Wikipedia:Requested articles/list of missing pharmacology - Wikipedia ...
On February 6, 2005, 80.168.225.145 dumped an enormous list of pharmacology terms on to the Applied Sciences request page. Since this list is a dump from the public domain FDA ...
ESC> Congresses> ESC Congress 2007> Congress Reports 2007> Anti ...
Session Number: 710006 Session Title: The effect of the novel anti-oxidant AGI-1067 (succinobucol) on glycaemic control, new onset diabetes and clinical events in patients with a ...
Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a ...
Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. By - Dr Jean-Claude Tardif MD, John JV McMurray MD, Eric ...
Diabetes and Vascular Education - Dave.md - Library - Risk Factors
However, succinobucol was associated with a 19% reduction in secondary composite events consisting of the primary composite without unstable angina or revascularization (6.7% vs 8 ...
ACC: Novel drug treatment disappoints in ARISE study
But patients taking succinobucol had a 19% lower risk of cardiovascular death, cardiac arrest, MI or stroke compared with placebo. NEW ORLEANS | Preliminary results from the ...
New Antioxidant Drug Shows Promise Against Diabetes
Succinobucol is a chemical relative of probucol, a cholesterol-lowering drug taken off the market in the United States in 1995 because of side effects.
ESC Congress 2007 ΠSlides - Clinical Trial Update II ΠPfeffer
Introduction • Oxidative stress and inflammation are involved in the pathophysiology of atherosclerosis and pancreatic beta-cell failure and insulin resistance • Succinobucol ...
Defeat Diabetes Foundation -- Antioxidant Achieves a 64% Reduction In ...
Succinobucol failed to achieve a significant impact on the primary end point, a composite of “hard” atherosclerotic outcomes and the “soft” end points of coronary ...
ARMC Health Information
Succinobucol is a chemical relative of probucol, a cholesterol-lowering drug taken off the market in the United States in 1995 because of side effects.
VascularWeb: Vascular Specialist Volume 3 Number 3
NEW ORLEANS -- Succinobucol, a novel antioxidant with anti-inflammatory properties, achieved a 64% reduction in new-onset diabetes in patients with a recent acute coronary syndrome ...
Effects of Succinobucol (AGI-1067) After an Acute Coronary Syndrome: A ...
Title: Effects of Succinobucol (AGI-1067) After an Acute Coronary Syndrome: A Randomised, Double-Blind, Placebo-Controlled Trial Topic: General Cardiology
